These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New drugs: ambrisentan, temsirolimus, and eculizumab. Hussar DA J Am Pharm Assoc (2003); 2007; 47(5):664, 666-7, 669-71. PubMed ID: 17848357 [No Abstract] [Full Text] [Related]
5. Eculizumab in paroxysmal nocturnal hemoglobinuria. Takita M; Matsumura T; Kami M N Engl J Med; 2006 Dec; 355(26):2787; author reply 2787-8. PubMed ID: 17193722 [No Abstract] [Full Text] [Related]
6. Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Hill A Clin Adv Hematol Oncol; 2005 Nov; 3(11):849-50. PubMed ID: 16491626 [No Abstract] [Full Text] [Related]
7. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Dmytrijuk A; Robie-Suh K; Cohen MH; Rieves D; Weiss K; Pazdur R Oncologist; 2008 Sep; 13(9):993-1000. PubMed ID: 18784156 [TBL] [Abstract][Full Text] [Related]
8. Update on eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Hill A Clin Adv Hematol Oncol; 2008 Jul; 6(7):499-500. PubMed ID: 18654116 [No Abstract] [Full Text] [Related]
9. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Schrezenmeier H; Höchsmann B Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989 [TBL] [Abstract][Full Text] [Related]
10. [Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria]. Nau JY Rev Med Suisse; 2006 Oct; 2(81):2255. PubMed ID: 17076159 [No Abstract] [Full Text] [Related]
11. Eculizumab in paroxysmal nocturnal hemoglobinuria. Pride YB N Engl J Med; 2006 Dec; 355(26):2787; author reply 2787-8. PubMed ID: 17195305 [No Abstract] [Full Text] [Related]
12. Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure. Kelly RJ; Hill A; Arnold LM; Khursigara G; Kanagasundaram NS; Hillmen P Leuk Res; 2011 Apr; 35(4):560-2. PubMed ID: 21145109 [No Abstract] [Full Text] [Related]
13. Cardiopulmonary bypass in a patient with classic paroxysmal nocturnal hemoglobinuria during treatment with eculizumab. van Bijnen ST; Vermeer H; Mourisse JM; de Witte T; van Swieten HA; Muus P Eur J Haematol; 2011 Oct; 87(4):376-8. PubMed ID: 21623921 [No Abstract] [Full Text] [Related]
14. Eculizumab in paroxysmal nocturnal hemoglobinuria. Singh J; Malani AK; Pabla M N Engl J Med; 2006 Dec; 355(26):2786; author reply 2787-8. PubMed ID: 17195307 [No Abstract] [Full Text] [Related]
15. Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5. Balagula Y; Newman SB; Lacouture ME Am J Hematol; 2010 May; 85(5):392-3. PubMed ID: 20232400 [No Abstract] [Full Text] [Related]
16. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria. Berzuini A; Montanelli F; Prati D N Engl J Med; 2010 Sep; 363(10):993-4. PubMed ID: 20818912 [No Abstract] [Full Text] [Related]
17. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab. Danilov AV; Smith H; Craigo S; Feeney DM; Relias V; Miller KB Leuk Res; 2009 Jun; 33(6):e4-5. PubMed ID: 18952283 [No Abstract] [Full Text] [Related]
18. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria. Knoll BM; Letendre L; Steensma DP Am J Hematol; 2008 Nov; 83(11):881-3. PubMed ID: 18756538 [No Abstract] [Full Text] [Related]